UNSPSC 51343812: Dolutegravir/emitricitabine/tenofovir alafenamide

This classification denotes a combination drug for treatment of HIV. The first component, DOLUTEGRAVIR, has US FDA Unique Ingredient Identifier of DKO1W9H7M1. The second component, EMTRICITABINE, has US FDA Unique Ingredient Identifier of G70B4ETF4S. The third component, TENOFOVIR ALAFENAMIDE, has US FDA Unique Ingredient Identifier of EL9943AG5J.

UNSPSC 51343812 Dolutegravir/emitricitabine/tenofovir alafenamide is a Commodity code that names a single antiretroviral combination product for HIV treatment; however, the recent opportunities record shows no active state or local solicitations directly procuring this drug.

The available opportunities in the dataset reflect tangential pharmaceutical and medical supply activity across health departments, fire departments, and forensic labs—naloxone procurement by Seminole County, Florida; BLS/ALS pharmaceuticals and EMS supplies by the City of Tucson Fire Department; certified drug reference standards by Pinellas County, Florida for forensic analysis; and generic multi-source pharmaceuticals through the Minnesota Multistate Cooperative Purchasing Alliance—but none target dolutegravir/emitricitabine/tenofovir alafenamide specifically. The code shows no recent activity at the state or local level that aligns with this HIV treatment regimen.